Preclinical evaluation of Ezetimibe for repurposing to pulmonary fibrosis.
Conclusions: Ezetimibe may be repurposed for treating lung fibrosis. Further clinical validation is needed. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Lee, C., Kwak, S. H., Han, J., Shin, J. H., Lee, Y. S., Park, J. S., Lim, B. J., Lee, J. G., Kim, Y. S., Kim, S. Y., Bae, S. H. Tags: Idiopathic interstitial pneumonias Source Type: research
Mortality and Lung Function Decline of Idiopathic Pulmonary Fibrosis Patient with Ezetimibe and Pirfenidone
Conclusions: Ezetimibe may decrease the mortality and lung function decline in IPF patients. But furthur prospective validation clinical study is required. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Cho, J., Lee, C., Kwak, S. H., Kim, Y. S. Tags: Idiopathic interstitial pneumonias Source Type: research
Low-density Lipoprotein Cholesterol Reduction Therapies for Secondary Prevention in Patients with Stroke: A Network Meta-analysis
CONCLUSION: Treatment with ezetimibe plus statins was suggested as the most efficacious in decreasing the incidence of recurrent stroke. The analysis also revealed that statin monotherapy was related to an increased risk of hemorrhagic stroke.PMID:37881090 | DOI:10.2174/1570159X22666231020093035 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - October 26, 2023 Category: Drugs & Pharmacology Authors: Xing Wang Jun Zheng Yuqi Chen Chao You Lu Ma Source Type: research
A retrospective study of people with familial hypercholesterolaemia in a Belgian lipid clinic
CONCLUSIONS: In this Belgian population, people with heterozygous FH remain undertreated. Reaching treatment targets in FH seems possible, although this requires combination treatment (with PCSK9-targeted therapy) in most patients. Earlier diagnosis of FH, more extensive lipid-lowering treatment and reimbursement options and a more holistic approach are needed to lower LDL-C and cardiovascular risk in patients with FH.PMID:37882513 | DOI:10.1080/00015385.2023.2266647 (Source: Acta Cardiologica)
Source: Acta Cardiologica - October 26, 2023 Category: Cardiology Authors: V Ide D De Cock S Pazmino R Vangoitsenhoven B Van der Schueren A Mertens Source Type: research
Low-density Lipoprotein Cholesterol Reduction Therapies for Secondary Prevention in Patients with Stroke: A Network Meta-analysis
CONCLUSION: Treatment with ezetimibe plus statins was suggested as the most efficacious in decreasing the incidence of recurrent stroke. The analysis also revealed that statin monotherapy was related to an increased risk of hemorrhagic stroke.PMID:37881090 | DOI:10.2174/1570159X22666231020093035 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - October 26, 2023 Category: Drugs & Pharmacology Authors: Xing Wang Jun Zheng Yuqi Chen Chao You Lu Ma Source Type: research
A retrospective study of people with familial hypercholesterolaemia in a Belgian lipid clinic
CONCLUSIONS: In this Belgian population, people with heterozygous FH remain undertreated. Reaching treatment targets in FH seems possible, although this requires combination treatment (with PCSK9-targeted therapy) in most patients. Earlier diagnosis of FH, more extensive lipid-lowering treatment and reimbursement options and a more holistic approach are needed to lower LDL-C and cardiovascular risk in patients with FH.PMID:37882513 | DOI:10.1080/00015385.2023.2266647 (Source: Acta Cardiologica)
Source: Acta Cardiologica - October 26, 2023 Category: Cardiology Authors: V Ide D De Cock S Pazmino R Vangoitsenhoven B Van der Schueren A Mertens Source Type: research
Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention
CONCLUSION: Immediate initiation of high-intensity statin and ezetimibe treatment might be considered as the default strategy in treatment-naïve patients with high admission LDL‑C undergoing PCI.PMID:37874347 | DOI:10.1007/s00508-023-02296-z (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 24, 2023 Category: General Medicine Authors: Achim Leo Burger Nora Beran Edita Pogran Christoph C Kaufmann David Zweiker Marie Muthspiel Benjamin Panzer Bernhard J äger Miklos Rohla Kurt Huber Source Type: research
Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention
CONCLUSION: Immediate initiation of high-intensity statin and ezetimibe treatment might be considered as the default strategy in treatment-naïve patients with high admission LDL‑C undergoing PCI.PMID:37874347 | DOI:10.1007/s00508-023-02296-z (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 24, 2023 Category: General Medicine Authors: Achim Leo Burger Nora Beran Edita Pogran Christoph C Kaufmann David Zweiker Marie Muthspiel Benjamin Panzer Bernhard J äger Miklos Rohla Kurt Huber Source Type: research
Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention
CONCLUSION: Immediate initiation of high-intensity statin and ezetimibe treatment might be considered as the default strategy in treatment-naïve patients with high admission LDL‑C undergoing PCI.PMID:37874347 | DOI:10.1007/s00508-023-02296-z (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 24, 2023 Category: General Medicine Authors: Achim Leo Burger Nora Beran Edita Pogran Christoph C Kaufmann David Zweiker Marie Muthspiel Benjamin Panzer Bernhard J äger Miklos Rohla Kurt Huber Source Type: research
Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention
CONCLUSION: Immediate initiation of high-intensity statin and ezetimibe treatment might be considered as the default strategy in treatment-naïve patients with high admission LDL‑C undergoing PCI.PMID:37874347 | DOI:10.1007/s00508-023-02296-z (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 24, 2023 Category: General Medicine Authors: Achim Leo Burger Nora Beran Edita Pogran Christoph C Kaufmann David Zweiker Marie Muthspiel Benjamin Panzer Bernhard J äger Miklos Rohla Kurt Huber Source Type: research
Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention
CONCLUSION: Immediate initiation of high-intensity statin and ezetimibe treatment might be considered as the default strategy in treatment-naïve patients with high admission LDL‑C undergoing PCI.PMID:37874347 | DOI:10.1007/s00508-023-02296-z (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 24, 2023 Category: General Medicine Authors: Achim Leo Burger Nora Beran Edita Pogran Christoph C Kaufmann David Zweiker Marie Muthspiel Benjamin Panzer Bernhard J äger Miklos Rohla Kurt Huber Source Type: research
Low-density lipoprotein cholesterol reduction with immediate combination therapy of statin and ezetimibe compared to statin monotherapy after percutaneous coronary intervention
CONCLUSION: Immediate initiation of high-intensity statin and ezetimibe treatment might be considered as the default strategy in treatment-naïve patients with high admission LDL‑C undergoing PCI.PMID:37874347 | DOI:10.1007/s00508-023-02296-z (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 24, 2023 Category: General Medicine Authors: Achim Leo Burger Nora Beran Edita Pogran Christoph C Kaufmann David Zweiker Marie Muthspiel Benjamin Panzer Bernhard J äger Miklos Rohla Kurt Huber Source Type: research
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Korean J Intern Med. 2023 Oct 20. doi: 10.3904/kjim.2023.243. Online ahead of print.ABSTRACTDyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetimibe, a cholesterol absorption inhibitor, offers a potential non-statin therapy to optimize LDL-C management. Key clinical trials, such as IMPROVE-IT and RACING, have demonstrated that the addition of ezetimibe to statin therapy leads to f...
Source: The Korean Journal of Internal Medicine - October 22, 2023 Category: Internal Medicine Authors: Jeongmin Lee Seung-Hwan Lee Source Type: research
